Project 5: Unraveling mechanisms for neurological diseases caused by ATAD3A mutations
Project 5: Unraveling mechanisms for neurological diseases caused by ATAD3A mutations
批准号:
10225578
负责人:
Wan Hee Yoon
金额:
$39.38万
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-03-01 至 2021-10-31
关键词:
ATP phosphohydrolaseAcidsAffectBiogenesisBiologyCardiolipinsCardiomyopathiesCellsCholesterolCholesterol HomeostasisComplexDNA biosynthesisDefectDevelopmental BiologyDiseaseDrosophila genusEthanolaminesExcretory functionExhibitsFamilyGeneticGenetic DiseasesGoalsHereditary Spastic ParaplegiaHomeostasisKnowledgeLinkMaintenanceMembraneMembrane LipidsMetabolismMitochondriaMitochondrial DNAMitochondrial DiseasesMitochondrial ProteinsMolecularMolecular ChaperonesMuscleMutateMutationNeurodegenerative DisordersNeurologicNeuronsOPA1 geneOklahomaOptic AtrophyPathogenicityPathologicPatientsPeripheral Nervous System DiseasesPharmaceutical PreparationsPhospholipidsPlayPontocerebellar hypoplasiaPreventionProteinsRoleSecondary toSiteSyndromeTestingTherapeuticVariantbasebrain malformationflyheart functioninduced pluripotent stem cellinsightlipid metabolismloss of functionmitochondrial dysfunctionmitochondrial membranemutantnervous system disordernew therapeutic targetpreventrespiratorytherapeutic target
中文摘要
项目总结/文摘
英文摘要
PROJECT SUMMARY/ABSTRACT
Mitochondrial dysfunction is a pathological feature of many neurodegenerative diseases. We recently discovered
that mutations in the mitochondrial protein ATAD3A (ATPase family, AAA domain containing 3A) cause HAREL-
YOON syndrome, a disease characterized by peripheral neuropathy, optic atrophy, cardiomyopathy, and brain
malformation. ATAD3A is implicated in other neurological genetic diseases, including hereditary spastic
paraplegia, and congenital pontocerebellar hypoplasia, with abnormal cholesterol metabolism suggested as an
underlying cause. Although ATAD3A is known to influence mitochondrial biology and lipid metabolism, how
mutations in ATAD3A cause disease is unknown. There is an urgent need to fill this knowledge gap in order to
prevent or treat ATAD3A-associated and other mitochondrial diseases, most of which have no known cure.
Our long-term goal is to discover new therapeutic targets and strategies for mitochondrial diseases. The
objective of our proposal is to uncover the mechanisms by which ATAD3A controls mitochondrial functions, using
Drosophila and ATAD3A patient-derived induced pluripotent stem cells. Our CENTRAL HYPOTHESIS is that
ATAD3A regulates mitochondrial membrane lipid homeostasis, and thus mitochondrial membrane dynamics,
mitochondrial DNA (mtDNA) replication, and lipid metabolism, based on the following compelling evidence. First,
ATAD3A plays a role in the formation of ER-mitochondria contact sites (EMCS) which are essential for import
and synthesis of phospholipids. Second, ATAD3A is essential for importing cholesterol into mitochondria as well
as maintaining cholesterol-rich mitochondria membrane structures. Lastly, patients carrying ATAD3A mutations
exhibit increased 3-methylglutaconic acid excretion, which is often caused by a deficiency in mitochondrial
respiratory complexes secondary to defects in cardiolipin remodeling. We expect that mechanistic insight into
the consequences of ATADA3 mutations derived from our studies will reveal unanticipated therapeutic targets
for prevention or treatment of a variety of mitochondrial diseases. We will test our central hypothesis by
performing the following Specific Aims: (1) Elucidate how ATAD3A regulates mitochondrial membrane dynamics;
(2) Determine how ATAD3A promotes mtDNA replication in neurons; and (3) Determine how ATAD3A regulates
proper heart function.
Upon conclusion of our studies, we expect to uncover how ATAD3A modulates mitochondria membrane
dynamics, biogenesis, and heart function. Understanding how ATAD3A links diverse aspects of mitochondrial
biology is expected to have a positive impact by revealing the molecular basis, as well as novel therapeutic
targets and strategies for ATAD3A-associated diseases and other disorders caused by mitochondrial
dysfunction.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Role of ATAD3A in Lysosomal Homeostasis and Neurogenesis
-
批准号:10185309
-
项目类别:
-
资助金额:$45.2万
-
财政年份:2021
-
负责人:Wan Hee Yoon
-
依托单位:
Role of ATAD3A in Lysosomal Homeostasis and Neurogenesis
-
批准号:10680398
-
项目类别:
-
资助金额:$43.33万
-
财政年份:2021
-
负责人:Wan Hee Yoon
-
依托单位:
Role of ATAD3A in Lysosomal Homeostasis and Neurogenesis
-
批准号:10413855
-
项目类别:
-
资助金额:$43.33万
-
财政年份:2021
-
负责人:Wan Hee Yoon
-
依托单位:
国内基金
海外基金
登录
查看更多内容
具有抗癌活性的天然产物金霉酸(Aureolic acids)全合成与选择性构建2-脱氧糖苷键
-
批准号:22007039
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:王黎明
-
依托单位:
海洋放线菌来源聚酮类化合物Pteridic acids生物合成机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2019
-
负责人:朱义广
-
依托单位:
手性Lewis Acids催化的分子内串联1,5-氢迁移/环合反应及其在构建结构多样性手性含氮杂环化合物中的应用
-
批准号:21372217
-
项目类别:面上项目
-
资助金额:80.0万元
-
批准年份:2013
-
负责人:袁伟成
-
依托单位:
对空气稳定的新型的有机金属Lewis Acids催化剂制备、表征与应用研究
-
批准号:21172061
-
项目类别:面上项目
-
资助金额:30.0万元
-
批准年份:2011
-
负责人:许新华
-
依托单位:
钛及含钛Lewis acids促臭氧/过氧化氢体系氧化性能的广普性、高效性及其机制
-
批准号:21176225
-
项目类别:面上项目
-
资助金额:60.0万元
-
批准年份:2011
-
负责人:童少平
-
依托单位:
基于Zip Nucleic Acids引物对高度降解和低拷贝DNA检材的STR分型研究
-
批准号:81072511
-
项目类别:面上项目
-
资助金额:31.0万元
-
批准年份:2010
-
负责人:严江伟
-
依托单位:
海洋天然产物Makaluvic acids 的全合成及其对南海鱼虱存活的影响
-
批准号:30660215
-
项目类别:地区科学基金项目
-
资助金额:21.0万元
-
批准年份:2006
-
负责人:王世范
-
依托单位: